scholarly journals Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients

Diabetologia ◽  
2000 ◽  
Vol 43 (5) ◽  
pp. 598-608 ◽  
Author(s):  
U. Roll ◽  
C. W. Turck ◽  
S. E. Gitelman ◽  
S. M. Rosenthal ◽  
M. S. Nolte ◽  
...  

1985 ◽  
Vol 54 (02) ◽  
pp. 413-414 ◽  
Author(s):  
Margarethe Geiger ◽  
Bernd R Binder

SummaryWe have demonstrated previously that fibrin enhanced plasmin formation by the vascular plasminogen activator was significantly impaired, when components isolated from the plasma of three uncontrolled diabetic patients (type I) were used to study plasminogen activation in vitro. In the present study it can be demonstrated that functional properties of the vascular plasminogen activators as well as of the plasminogens from the same three diabetic patients are significantly improved after normalization of blood sugar levels and improvement of HbAlc values. Most pronounced the Km of diabetic vascular plasminogen activator in the presence of fibrin returned to normal values, and for diabetic plasminogen the prolonged lag period until maximal plasmin formation occurred was shortened to almost control values. From these data we conclude that the observed abnormalities of in vitro fibrinolysis are not primarily associated with the diabetic disease, but might be secondary to metabolic disorders caused by diabetes.



Diabetes ◽  
1988 ◽  
Vol 37 (4) ◽  
pp. 462-466 ◽  
Author(s):  
U. Di Mario ◽  
F. Dotta ◽  
L. Crisa ◽  
E. Anastasi ◽  
D. Andreani ◽  
...  


Diabetes ◽  
1989 ◽  
Vol 38 (4) ◽  
pp. 524-533 ◽  
Author(s):  
H. Wahrenberg ◽  
F. Lonnqvist ◽  
P. Engfeldt ◽  
P. Arner
Keyword(s):  


Diabetes ◽  
1987 ◽  
Vol 36 (1) ◽  
pp. 73-79 ◽  
Author(s):  
W. L. Kupin ◽  
P. Cortes ◽  
F. Dumler ◽  
C. S. Feldkamp ◽  
M. C. Kilates ◽  
...  


Diabetes ◽  
1989 ◽  
Vol 38 (3) ◽  
pp. 310-315 ◽  
Author(s):  
C. Giordano ◽  
F. Panto ◽  
C. Caruso ◽  
M. A. Modica ◽  
A. M. Zambito ◽  
...  


Diabetes ◽  
1985 ◽  
Vol 34 (5) ◽  
pp. 510-519 ◽  
Author(s):  
D. C. Robbins ◽  
S. E. Shoelson ◽  
H. S. Tager ◽  
P. M. Mead ◽  
D. H. Gaynor


2019 ◽  
Vol 14 (2) ◽  
pp. 146-151 ◽  
Author(s):  
Junaid Khan ◽  
Amit Alexander ◽  
Mukta Agrawal ◽  
Ajazuddin ◽  
Sunil Kumar Dubey ◽  
...  

Diabetes and its complications are a significant health concern throughout the globe. There are physiological differences in the mechanism of type-I and type-II diabetes and the conventional drug therapy as well as insulin administration seem to be insufficient to address the problem at large successfully. Hypoglycemic swings, frequent dose adjustments and resistance to the drug are major problems associated with drug therapy. Cellular approaches through stem cell based therapeutic interventions offer a promising solution to the problem. The need for pancreatic transplants in case of Type- I diabetes can also be by-passed/reduced due to the formation of insulin producing β cells via stem cells. Embryonic Stem Cells (ESCs) and induced Pluripotent Stem Cells (iPSCs), successfully used for generating insulin producing β cells. Although many experiments have shown promising results with stem cells in vitro, their clinical testing still needs more exploration. The review attempts to bring into light the clinical studies favoring the transplantation of stem cells in diabetic patients with an objective of improving insulin secretion and improving degeneration of different tissues in response to diabetes. It also focuses on the problems associated with successful implementation of the technique and possible directions for future research.



Lipids ◽  
2008 ◽  
Vol 43 (6) ◽  
pp. 485-497 ◽  
Author(s):  
Sid Ahmed Merzouk ◽  
Meriem Saker ◽  
Karima Briksi Reguig ◽  
Nassima Soulimane ◽  
Hafida Merzouk ◽  
...  


2013 ◽  
Vol 114 (9) ◽  
pp. 1282-1290 ◽  
Author(s):  
Luis Puente-Maestu ◽  
Alberto Lázaro ◽  
Blanca Humanes

Mitochondrial muscle alterations are common in patients with chronic obstructive pulmonary disease (COPD) and manifest mainly as decreased oxidative capacity and excessive production of reactive oxygen species (ROS). The significant loss of oxidative capacity observed in the quadriceps of COPD patients is mainly due to reduced mitochondrial content in the fibers, a finding consistent with the characteristic loss of type I fibers observed in that muscle. Decreased oxidative capacity does not directly limit maximum performance; however, it is associated with increased lactate production at lower exercise intensity and reduced endurance. Since type I fiber atrophy does not occur in respiratory muscles, the loss of such fibers in the quadriceps could be to the result of disuse. In contrast, excessive production of ROS and oxidative stress are observed in both the respiratory muscles and the quadriceps of COPD patients. The causes of increased ROS production are not clear, and a number of different mechanisms can play a role. Several mitochondrial alterations in the quadriceps of COPD patients are similar to those observed in diabetic patients, thus suggesting a role for muscle alterations in this comorbidity. Amino acid metabolism is also altered. Expression of peroxisome proliferator-activated receptor-γ coactivator-1α mRNA is low in the quadriceps of COPD patients, which could also be a consequence of type I fiber loss; nevertheless, its response to exercise is not altered. Patterns of muscle cytochrome oxidase gene activation after training differ between COPD patients and healthy subjects, and the profile is consistent with hypoxic stress, even in nonhypoxic patients.



Sign in / Sign up

Export Citation Format

Share Document